Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients

Nicholaos C Bellos, MD51 enrolled

Overview

Hypotension does not occur with Maraviroc at a dose of 600 mg/day

A qualitative description of orthostatic hypotension in patients receiving once daily Maraviroc at 600 mg with Epzicom measured by a validated questionnaire

Study Type

OBSERVATIONAL

Enrollment

Conditions

Drug-induced Hypotension

Eligibility

Sex: ALLMin age: 21 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Epzicom Maraviroc once daily dosing Exclusion Criteria: * Maraviroc with any other back bone

Outcomes

Primary Outcomes

Hypotension related to once daily Maraviroc dosing

Blood pressure lowering secondary to Maraviroc 600 mg once daily dosing

Time frame: 48 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.